Kutlu Ramazan, Dag Nurullah, Saparbekov Eldiiar, Yagin Fatma Hilal
Department of Radiology & Liver Transplantation Institute, Faculty of Medicine, Inonu University, Malatya, Turkey.
Department of Radiology & Liver Transplantation Institute, Faculty of Medicine, Inonu University, Malatya, Turkey.
J Vasc Interv Radiol. 2025 May;36(5):787-794. doi: 10.1016/j.jvir.2025.01.042. Epub 2025 Jan 28.
To evaluate changes in nontarget hepatic hemangiomas, which are neither subjected to embolization nor targeted for treatment, following selective bleomycin-ethiodized oil transarterial chemoembolization (TACE) of a giant hepatic hemangioma.
This single-center, retrospective study included 24 patients with nontarget hepatic hemangiomas distinct from primary giant hemangiomas treated with selective bleomycin-ethiodized oil TACE between 2009 and 2022. The size and volume of the lesions were assessed using computed tomography (CT) scans obtained before treatment and at 6, 12, and 24 months.
A significant reduction in the size of nontarget lesions (n = 34) was observed during follow-up (P < .05). Eighteen of 34 lesions (53%) showed a reduction in volume of 50% or greater. Overall clinical success rate for the primary lesion, defined as a significant size reduction and symptom improvement, was 96%. Logistic regression analysis showed no statistically significant association between demographic or primary lesion variables and changes in nontarget lesions (P = .901). Spearman correlation analysis revealed no significant relationship between changes in primary and nontarget lesions (P > .05).
Bleomycin-ethiodized oil TACE of a giant hepatic hemangioma significantly reduced the size of untreated, nontarget hemangiomas. This may be related to systemic absorption of the chemotherapeutic agent, lymphatic dissemination, or an abscopal effect, although the exact mechanism remains unclear.
评估在对巨大肝血管瘤进行选择性博来霉素-碘化油经动脉化疗栓塞术（TACE）后，未接受栓塞治疗或未作为治疗靶点的非靶肝血管瘤的变化情况。
这项单中心回顾性研究纳入了24例患有非靶肝血管瘤的患者，这些血管瘤与2009年至2022年间接受选择性博来霉素-碘化油TACE治疗的原发性巨大血管瘤不同。使用治疗前以及治疗后6个月、12个月和24个月获得的计算机断层扫描（CT）评估病变的大小和体积。
在随访期间观察到非靶病变（n = 34）的大小显著减小（P < .05）。34个病变中有18个（53%）体积减小了50%或更多。原发性病变的总体临床成功率定义为大小显著减小和症状改善，为96%。逻辑回归分析显示，人口统计学或原发性病变变量与非靶病变变化之间无统计学显著关联（P = .901）。Spearman相关性分析显示原发性病变和非靶病变的变化之间无显著关系（P > .05）。
巨大肝血管瘤的博来霉素-碘化油TACE显著减小了未治疗的非靶血管瘤的大小。这可能与化疗药物的全身吸收、淋巴扩散或远隔效应有关，尽管确切机制尚不清楚。
